Catalyst Pharmaceutical Partners is heralding positive late-stage results for its lead drug, planning to make its case to the FDA in hopes of winning approval for a much-scrutinized orphan treatment.
Shares of Catalyst Pharmaceutical Partners got a boost from the news that its late-stage drug Firdapse had passed a cardio safety test.
The treatment, Firdapse, is marketed in Europe by BioMarin and is now in a Phase III study designed to win an FDA approval. And the company's shares, battered last fall after its lead drug flopped in a Phase IIb trial for cocaine addiction, instantly zoomed up 48% on the news.
Catalyst Pharmaceutical Partners ($CPRX) says that its cocaine addiction therapy flopped in a Phase IIb study, missing primary and secondary endpoints and triggering a collapse in its share price, which tumbled 65% on the news.
Catalyst Pharmaceutical Partners' (CPRX) badly battered shares skyrocketed 86 percent after the developer announced that a close analysis of data from a failed mid-stage clinical trial inspired the
Catalyst Pharmaceutical Partners says its lead drug candidate CPP-109, a treatment for cocaine addiction, failed to meet its primary endpoint in a mid-stage trial. Results from the trial did not show